Employees: 19
Size Arbutus Biopharma (ABUS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $630M, the 2524th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.11 on 18 Nov 2026.
Performance Over six months the shares fell 6.0%, against -25.9% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 1,142.6% over the last twelve months (peer median +5.5%); the operating margin is 80.1% (peer median 4.4%).
Valuation It trades at 1.6× enterprise value to sales against a peer median of 3.3× (3rd cheapest of 17).
Short interest Short interest is 10.0% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $181M | $14.1M | $6.17M | $18.1M | $39.0M |
| Revenue growth | — | +128% | -66% | -54% | — |
| Gross profit | $181M | $13.7M | $4.79M | $16.7M | $37.6M |
| EBITDA | $145M | -$26.7M | -$68.6M | -$76.6M | -$61.8M |
| Net income | $220M | -$33.5M | -$69.9M | -$72.8M | -$69.5M |
| Free cash flow | n/a | -$39.6M | -$65.0M | -$86.9M | -$35.9M |
| Capital expenditure | $0 | $0 | $182,000 | $1.01M | $512,000 |
| Total debt | $3.31M | $4.19M | $6.12M | $8.72M | $12.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABUS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.1% | -10.7% | 8th highest of 20 |
| 6-month return | -6.0% | -25.9% | 5th highest of 20 |
| Distance from 52-week high | -24.6% | -39.9% | 5th highest of 20 |
| Revenue growth (TTM) | +1,142.6% | +5.5% | highest of 17 |
| Operating margin | 80.1% | 4.4% | highest of 16 |
| EV / Sales | 1.6× | 3.3× | 3rd cheapest of 17 |
| EV / EBITDA | 2.0× | 14.5× | cheapest of 6 |
| Net debt / EBITDA | -2.3× | 0.7× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | 5.3× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 3.4× | 27.1% | +31.4% |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | 2.0× | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | 2.4× | 25.2% | +10.3% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 7.5× | n/a | n/a |